Cargando…

Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3‐iodothyronamine

Complex diseases such as polycystic ovary syndrome (PCOS) are associated with intricate pathophysiological, hormonal, and metabolic feedbacks that make their early diagnosis challenging, thus increasing the prevalence risks for obesity, cardiovascular, and fatty liver diseases. To explore the crosst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selen Alpergin, Ebru S., Bolandnazar, Zeinab, Sabatini, Martina, Rogowski, Michael, Chiellini, Grazia, Zucchi, Riccardo, Assadi‐Porter, Fariba M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256158/ https://www.ncbi.nlm.nih.gov/pubmed/28082426 http://dx.doi.org/10.14814/phy2.13097

Ejemplares similares

Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression
por: Assadi-Porter, Fariba M., et al.
Publicado: (2018)

Update on 3-iodothyronamine and its neurological and metabolic actions
por: Zucchi, Riccardo, et al.
Publicado: (2014)

Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway
por: Rogowski, Michael, et al.
Publicado: (2019)

Uptake of 3‐iodothyronamine hormone analogs inhibits the growth and viability of cancer cells
por: Rogowski, Michael, et al.
Publicado: (2017)

3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?
por: Rutigliano, Grazia, et al.
Publicado: (2020)

Modulation of cardiac ionic homeostasis by 3-iodothyronamine
por: Ghelardoni, Sandra, et al.
Publicado: (2009)

Modulation of Gene Expression by 3-Iodothyronamine: Genetic Evidence for a Lipolytic Pattern
por: Mariotti, Veronica, et al.
Publicado: (2014)

New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection
por: Bellusci, Lorenza, et al.
Publicado: (2017)

Metabolic Reprogramming in Health and Disease
por: Chiellini, Grazia
Publicado: (2020)

3-Iodothyronamine Affects Thermogenic Substrates’ Mobilization in Brown Adipocytes
por: Gencarelli, Manuela, et al.
Publicado: (2020)

Endogenous 3-Iodothyronamine (T1AM) and Synthetic Thyronamine-Like Analog SG-2 Act as Novel Pleiotropic Neuroprotective Agents through the Modulation of SIRT6
por: Bellusci, Lorenza, et al.
Publicado: (2020)

Thyroxine metabolite-derived 3-iodothyronamine (T1AM) and synthetic analogs as efficient suppressors of transthyretin amyloidosis
por: Kim, Bokyung, et al.
Publicado: (2023)

Maternal Lipid Metabolism Directs Fetal Liver Programming following Nutrient Stress
por: Bowman, Caitlyn E., et al.
Publicado: (2019)

Effect of Combined Levothyroxine (L-T(4)) and 3-Iodothyronamine (T(1)AM) Supplementation on Memory and Adult Hippocampal Neurogenesis in a Mouse Model of Hypothyroidism
por: Rutigliano, Grazia, et al.
Publicado: (2023)

Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome
por: Głuszak, Olgierd, et al.
Publicado: (2012)

Metabolic effects of polycystic ovary syndrome in adolescents
por: Han, Yejin, et al.
Publicado: (2015)

Cortisol-Metabolizing Enzymes in Polycystic Ovary Syndrome
por: Blumenfeld, Zeev, et al.
Publicado: (2016)

Metabolic Deregulations in Patients with Polycystic Ovary Syndrome
por: Jabczyk, Marzena, et al.
Publicado: (2023)

Metabolic Syndrome in Patients with Polycystic Ovary Syndrome in Iran
por: Zahiri, Ziba, et al.
Publicado: (2016)

The Polycystic Ovary Syndrome: An update on metabolic and hormonal mechanisms
por: Dumitrescu, R, et al.
Publicado: (2015)

Immunological and Metabolic Causes of Infertility in Polycystic Ovary Syndrome
por: Kicińska, Aleksandra Maria, et al.
Publicado: (2023)

Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china
por: Huang, Jia, et al.
Publicado: (2010)

Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome
por: Kumar, Amar Nagesh, et al.
Publicado: (2016)

Alterations of Sphingolipid Metabolism in Different Types of Polycystic Ovary Syndrome
por: Li, Juan, et al.
Publicado: (2019)

The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population
por: Dargham, Soha R., et al.
Publicado: (2017)

Predictors of Metabolic Syndrome among Polycystic Ovary Syndrome Sisters
por: Kulshreshtha, Bindu, et al.
Publicado: (2019)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
por: Herman, Rok, et al.
Publicado: (2023)

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
por: Mastnak, Lara, et al.
Publicado: (2023)

The mitochondrial carrier SFXN1 is critical for complex III integrity and cellular metabolism
por: Acoba, Michelle Grace, et al.
Publicado: (2021)

Metformin abrogates pathological TNF-α-producing B cells through mTOR-dependent metabolic reprogramming in polycystic ovary syndrome
por: Xiao, Na, et al.
Publicado: (2022)

Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
por: Shahebrahimi, Karoon, et al.
Publicado: (2016)

Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome
por: Mansour, Asieh, et al.
Publicado: (2016)

Traditional Persian Medicine and management of metabolic dysfunction in polycystic ovary syndrome
por: Hosseinkhani, Ayda, et al.
Publicado: (2017)

Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity
por: Couto Alves, A, et al.
Publicado: (2017)

Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women
por: de Medeiros, Sebastião Freitas, et al.
Publicado: (2017)

Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome
por: Kempegowda, Punith, et al.
Publicado: (2020)

Vitamin D, Bone Metabolism, and Fracture Risk in Polycystic Ovary Syndrome
por: Di Bari, Flavia, et al.
Publicado: (2021)

Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome
por: Kałużna, Małgorzata, et al.
Publicado: (2021)

Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation
por: Dumesic, Daniel A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4f0vssqnl6khp0cte8j6qrr2cd